B2BROKER-GROUP
26.8.2021 15:04:33 CEST | Business Wire | Press release
B2Broker Group is pleased to officially announce the launch of its venture fund, B2Broker VC. B2Broker VC is led by a team that is one of the most successful and fast-growing financial technology groups with in-depth expertise in sectors ranging from IT development to capital management. The venture fund will enable the investment in, and nurture of external projects that are of interest such as new fintech startups and payment systems, and will create synergies for the group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210826005497/en/
First Ventures
Back in 2017, like many other tech industry giants, B2Broker Group started working on its own internal corporate venture fund. This was focused on the development of a number of specific projects. Since then, the capitalisation of the group’s fund has grown steadily and now includes a number of projects in which the company has invested over $15 million so far. This is an exciting project which has enabled the development of a modern financial and technological ecosystem on the basis of the B2Broker group of companies.
Of particular focus is the launch of B2BinPay in 2017, a payment system which has become one of the most modern and technologically progressive platforms in the world, B2BX , a platform for the trading of digital assets which is licenced in the EU, Eqwire, a digital banking service, and last but not least, the group’s most expensive and complex project, B2Prime, which is an integrated liquidity provider with licences in different jurisdictions, including Europe and CIS.
External Projects
With the experience acquired on these internal projects and the business-processes that have been developed, B2Broker VC has also started investing in external projects. One of the most noteworthy of these is the innovative Coinsbuy, a project designed to cater for the growing demand for buying crypto using a credit or debit card. This will be a complementary project to B2Broker’s ecosystem.
Throughout this process, B2Broker VC identified the most interesting sectors such as fintech, IT development and automation, as well as startups offering products for the brokerage market.
Procedures and Stages
The most important aspect that the group seeks in its partners is conscientiousness, a clear vision and a good understanding of the market. B2Broker VC considers all potential recipients of investments as long-term strategic partners who in partnership, will move towards global leadership in the various market sectors.
B2Broker VC always finds the most convenient way of investment and cooperation both through equity holding and via convertible loans, which make the terms of cooperation as flexible as possible.
Companies who wish to apply for funding follow a step-by-step procedure starting with the preparation of an application and documents. This is followed by a product performance evaluation, follow-up questions and a series of meetings and evaluations before the final decision is made. After the signing of various documents and agreements, the first tranche of investment will be released after a process which takes between 2-6 months.
The kind of projects that are of interest to B2Broker VC are ones that match the group’s goals and business model. These include:
● Fintech development: Products and services for Forex, securities, derivatives, CFD and crypto markets.
● IT development: Development of payment systems, trading and brokerage platforms, risk management systems, analytical systems.
We are particularly interested in companies who have Bridges Technology and plugins for MT4/5, Trading Platforms for FX/CFD trading and those who have built trading platforms for Crypto Perpetual Futures, Crypto Spot trading and Securities trading on Exchanges. We are also looking for HUB and liquidity aggregation solutions and technology for market making on crypto exchanges.
● Automation: Products in the field of automation of external systems and process automation services.
● Products/services suitable for B2Broker's ecosystem such as KYC solutions, marketing services, products and services for the brokerage market.
Companies that end up working with the B2Broker Group will be handed the keys to the development of a young company that includes both financial assistance and access to the group’s infrastructure, its offices, and development teams, as well as top financial and marketing expertise.
Applications
B2Broker VC carefully considers each application received and investigates the possible mechanisms of cooperation, regardless of the size of the company and entrepreneurial experience among the founders.
To submit your application and become a global leader with B2Broker VC email us at vc@b2broker.com or visit our website .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210826005497/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom